Induction and activation of P-glycoprotein by dihydroxylated xanthones protect against the cytotoxicity of the P-glycoprotein substrate paraquat

Archives of Toxicology

Volumn 88, Issue 4, 2014, Pages 937-951

  Silva, Renata ^a   Sousa, Emília ^a   Carmo, Helena ^a   Palmeira, Andreia ^a   Barbosa, Daniel José ^a   Gameiro, Mariline ^a   Pinto, Madalena ^a   De Lourdes Bastos, Maria ^a   Remião, Fernando ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Activation; Caco 2 cells; Induction; P glycoprotein; Paraquat; Xanthones

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIBODY; MULTIDRUG RESISTANCE PROTEIN; OXYGEN; PARAQUAT; RHODAMINE 123; XANTHONE DERIVATIVE; ABCB1 PROTEIN, HUMAN; HERBICIDE; PROTECTIVE AGENT;

ARTICLE; CELL PROTECTION; CELL STRAIN CACO 2; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MEMBRANE VESICLE; MODEL; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; AGONISTS; BIOSYNTHESIS; CACO 2 CELL LINE; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HYDROXYLATION; INTESTINE; METABOLISM; PATHOLOGY; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; TIME FACTOR; UPREGULATION;

CACO-2 CELLS; CELL SURVIVAL; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; HERBICIDES; HUMANS; HYDROXYLATION; INTESTINES; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; P-GLYCOPROTEINS; PARAQUAT; PROTECTIVE AGENTS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; UP-REGULATION; XANTHONES;

EID: 84897110064     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-014-1193-y     Document Type: Article

References (67)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398 (Pubitemid 29222564)
2. Balimane PV, Han YH, Chong S (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 8(1):E1-E13
3. Barta CA, Sachs-Barrable K, Feng F, Wasan KM (2008) Effects of monoglycerides on p-glycoprotein: modulation of the activity and expression in caco-2 cell monolayers. Mol Pharm 5(5):863-875
4. Biganzoli E, Cavenaghi LA, Rossi R, Brunati MC, Nolli ML (1999) Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics. Farmaco 54(9):594-599 (Pubitemid 29462620)
5. Castanheiro RAP, Pinto MMM, Silva AMS, Cravo SMM, Gales L, Damas AM, Nazareth N, Nascimento MSJ, Eaton G (2007) Dihydroxyxanthones prenylated derivatives: synthesis, structure elucidation, and growth inhibitory activity on human tumor cell lines with improvement of selectivity for MCF-7. Bioorganic Med Chem 15(18):6080-6088 (Pubitemid 47088964)
6. Chaudhary PM, Roninson IB (1993) Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85(8):632-639 (Pubitemid 23120508)
7. Chin K, Chauhan S, Pastan I, Gottesman M (1990) Regulation of mdr RNA levels in response to cytotoxic drugs in rodent cells. Cell Growth Differ 1(8):361-365
8. Coi A, Massarelli I, Murgia L, Saraceno M, Calderone V, Bianucci AM (2006) Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorganic Med Chem 14(9):3153-3159
9. Costa E, Sousa E, Nazareth N, Nascimento SJ, Pinto MMM (2010) Synthesis of xanthones and benzophenones as inhibitors of tumor cell growth. Lett Drug Des Discov 7(7):487-493
10. Dinis-Oliveira RJ, Duarte JA, Remiao F, Sanchez-Navarro A, Bastos ML, Carvalho F (2006a) Single high dose dexamethasone treatment decreases the pathological score and increases the survival rate of paraquat-intoxicated rats. Toxicology 227(1-2):73-85 (Pubitemid 44402856)
11. Dinis-Oliveira RJ, Remiao F, Duarte JA, Ferreira R, Sanchez Navarro A, Bastos ML, Carvalho F (2006b) P-glycoprotein induction: an antidotal pathway for paraquat-induced lung toxicity. Free Radic Biol Med 41(8):1213-1224 (Pubitemid 44466319)
12. Dorner B, Kuntner C, Bankstahl JP, Bankstahl M, Stanek J, Wanek T, Stundner G, Mairinger S, Loscher W, Muller M, Langer O, Erker T (2009) Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem 52(19):6073-6082
13. Dunn WJ, Hopfinger AJ (2002) 3D QSAR of flexible molecules using tensor representation. In: Kubinyi H, Folkers G, Martin YC (eds) 3D QSAR in drug design volume 3 recent advances, vol 3. Kluwer Academic Publishers, New York, pp 167-182
14. Fardel O, Lecureur V, Daval S, Corlu A, Guillouzo A (1997) Upregulation of P-glycoprotein expression in rat liver cells by acute doxorubicin treatment. Eur J Biochem 246(1):186-192 (Pubitemid 27229686)
15. Froimowitz M (1993) HyperChem: a software package for computational chemistry and molecular modeling. Biotechniques 14(6):1010-1013
16. Genoux-Bastide E, Lorendeau D, Nicolle E, Yahiaoui S, Magnard S, Di Pietro A, Baubichon-Cortay H, Boumendjel A (2011) Identification of xanthones as selective killers of cancer cells overexpressing the ABC transporter MRP1. ChemMedChem 6(8):1478-1484
17. Harmsen S, Meijerman I, Febus CL, Maas-Bakker RF, Beijnen JH, Schellens JH (2009) PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol 66(4):765-771
18. Hennessy M, Spiers JP (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacol Res 55(1):1-15 (Pubitemid 46108588)
19. Hu XF, Slater A, Rischin D, Kantharidis P, Parkin JD, Zalcberg J (1999) Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line. Br J Cancer 79(5-6):831-837 (Pubitemid 29082113)
20. Huynh-Delerme C, Huet H, Noel L, Frigieri A, Kolf-Clauw M (2005) Increased functional expression of P-glycoprotein in Caco-2 TC7 cells exposed long-term to cadmium. Toxicol In Vitro 19(4):439-447
21. Kageyama M, Fukushima K, Togawa T, Fujimoto K, Taki M, Nishimura A, Ito Y, Sugioka N, Shibata N, Takada K (2006) Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol Pharm Bull 29(4):779-784
22. Kanaan M, Daali Y, Dayer P, Desmeules J (2009) Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. Basic Clin Pharmacol Toxicol 105(3):199-206
23. Katritzky AR, Perumal S, Petrukhin R, Kleinpeter E (2001) CODESSA-based theoretical QSPR model for hydantoin HPLC-RT lipophilicities. J Chem Inf Comput Sci 41(3):569-574
24. Kim KA, Park PW, Liu KH, Kim KB, Lee HJ, Shin JG, Park JY (2008) Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. J Clin Pharmacol 48(1):66-72
25. Kim RB (2002) Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 34(1-2):47-54
26. Kubinyi H (2008) Statistical Methods. In: Mannhold R, Krogsgaard-Larsen P, Timmerman H (eds) QSAR: Hansch analysis and related approaches. Wiley-VCH Verlag GmbH, Weinheim, pp 91-107
27. Lill MA, Danielson ML (2010) Computer-aided drug design platform using PyMOL. J Comput Aided Mol Des 25(1):13-19
28. Litman T, Zeuthen T, Skovsgaard T, Stein WD (1997) Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1361(2):169-176 (Pubitemid 27362090)
29. Loo TW, Clarke DM (1993) Functional consequences of phenylalanine mutations in the predicted transmembrane domain of P-glycoprotein. J Biol Chem 268(27):19965-19972 (Pubitemid 23278889)
30. Loo TW, Clarke DM (2002) Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein. J Biol Chem 277(46):44332-44338 (Pubitemid 36157868)
31. Lü WJ, Chen YL, Ma WP, Zhang XY, Luan F, Liu MC, Chen XG, Hu ZD (2008) QSAR study of neuraminidase inhibitors based on heuristic method and radial basis function network. Eur J Med Chem 43(3):569-576
32. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58(3):624-632
33. Masters K-S, Bräse S (2012) Xanthones from fungi, lichens, and bacteria: the natural products and their synthesis. Chem Rev 112(7):3717-3776
34. Nielsen D, Eriksen J, Maare C, Jakobsen A, Skovsgaard T (1998) P-glycoprotein expression in Ehrlich ascites tumour cells after in vitro and in vivo selection with daunorubicin. Br J Cancer 78(9):1175-1180 (Pubitemid 28479147)
35. Palmeira A, Rodrigues F, Sousa E, Pinto M, Vasconcelos MH, Fernandes MX (2011) New uses for old drugs: pharmacophore-based screening for the discovery of P-glycoprotein inhibitors. Chem Biol Drug Des 78(1):57-72
36. Palmeira A, Vasconcelos MH, Paiva A, Fernandes MX, Pinto M, Sousa E (2012) Dual inhibitors of P-glycoprotein and tumor cell growth: (re)discovering thioxanthones. Biochem Pharmacol 83(1):57-68
37. Pedro M, Cerqueira F, Sousa MEl, Nascimento MSJ, Pinto M (2002) Xanthones as inhibitors of growth of human cancer cell lines and their effects on the proliferation of human lymphocytes In Vitro. Bioorg Med Chem 10(12):3725-3730 (Pubitemid 36164676)
38. Pinto MMM, Sousa ME, Nascimento MSJ (2005) Xanthone derivatives: new insights in biological activities. Curr Med Chem 12(21):2517-2538 (Pubitemid 41408417)
39. Safa AR (1993) Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest 11(1):46-56
40. Safa AR (1998) Photoaffinity labels for characterizing drug interaction sites of P-glycoprotein. Methods Enzymol 292:289-307
41. Safa AR (2004) Identification and characterization of the binding sites of P-glycoprotein for multidrug resistance-related drugs and modulators. Curr Med Chem Anticancer Agents 4(1):1-17
42. Seelig A (1998) A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem 251(1-2):252-261
43. Seeliger D, de Groot BL (2010) Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des 24(5):417-422
44. Shapiro AB, Ling V (1997) Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250(1):130-137 (Pubitemid 27504592)
45. Shapiro AB, Ling V (1998) The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol Scand Suppl 643:227-234 (Pubitemid 28439422)
46. Sharom FJ (2011) The P-glycoprotein multidrug transporter. Essays Biochem 50(1):161-178
47. Silva R, Carmo H, Dinis-Oliveira R, Cordeiro-da-Silva A, Lima SC, Carvalho F, de Bastos ML, Remiao F (2011) In vitro study of P-glycoprotein induction as an antidotal pathway to prevent cytotoxicity in Caco-2 cells. Arch Toxicol 85(4):315-326
48. Silva R, Carmo H, Vilas-Boas V, Pinho PG, Dinis-Oliveira RJ, Carvalho F, Silva I, Correia-de-Sa P, Bastos MD, Remiao F (2013) Doxorubicin decreases paraquat accumulation and toxicity in Caco-2 cells. Toxicol Lett 217(1):34-41
49. Sousa E, Palmeira A, Cordeiro A, Sarmento B, Ferreira D, Lima R, Helena Vasconcelos M, Pinto M (2013) Bioactive xanthones with effect on P-glycoprotein and prediction of intestinal absorption. Med Chem Res 22(5):2115-2123
50. Sterz K, Mollmann L, Jacobs A, Baumert D, Wiese M (2009) Activators of P-glycoprotein: structure-activity relationships and investigation of their mode of action. Chem Med Chem 4(11):1897-1911
51. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, Garberg P, Sjostrom B, Lundgren B, Artursson P (2001) Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J Pharmacol Exp Ther 299(1):164-170 (Pubitemid 32905131)
52. Takara K, Hayashi R, Kokufu M, Yamamoto K, Kitada N, Ohnishi N, Yokoyama T (2009) Effects of nonsteroidal anti-inflammatory drugs on the expression and function of P-glycoprotein/MDR1 in Caco-2 cells. Drug Chem Toxicol 32(4):332-337
53. Tchamo DN, Dijoux-Franca MG, Mariotte AM, Tsamo E, Daskiewicz JB, Bayet C, Barron D, Conseil G, Di Pietro A (2000) Prenylated xanthones as potential P-glycoprotein modulators. Bioorg Med Chem Lett 10(12):1343-1345 (Pubitemid 30391965)
54. Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y (2005) Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos 33(4):547-554 (Pubitemid 40393198)
55. Trott O, Olson AJ (2009) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455-461
56. Ueda K, Taguchi Y, Morishima M (1997) How does P-glycoprotein recognize its substrates? Semin Cancer Biol 8(3):151-159 (Pubitemid 28041012)
57. Varma MV, Ashokraj Y, Dey CS, Panchagnula R (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48(4):347-359 (Pubitemid 36945333)
58. Vilas-Boas V, Silva R, Gaio AR, Martins AM, Lima SC, Cordeiro-da- Silva A, de Bastos ML, Remiao F (2011) P-glycoprotein activity in human Caucasian male lymphocytes does not follow its increased expression during aging. Cytometry A 79(11):912-919
59. Vilas-Boas V, Silva R, Guedes-de-Pinho P, Carvalho F, Bastos ML, Remião F (2013a) RBE4 cells are highly resistant to paraquat-induced cytotoxicity: studies on uptake and efflux mechanisms. J App Toxicol, Epub ahead of print
60. Vilas-Boas V, Silva R, Nunes C, Reis S, Ferreira L, Vieira C, Carvalho F, Bastos Mde L, Remiao F (2013b) Mechanisms of P-gp inhibition and effects on membrane fluidity of a new rifampicin derivative, 1,8-dibenzoyl-rifampicin. Toxicol Lett 220(3):259-266
61. Vilas-Boas V, Silva R, Palmeira A, Sousa E, Ferreira LM, Branco PS, Carvalho F, MdL Bastos, Remião F (2013c) Development of novel rifampicin-derived P-glycoprotein activators/inducers. Synthesis, in silico analysis and application in the RBE4 Cell model, using paraquat as substrate. PLoS ONE 8(8):e74425
62. Walczac B, Daszykowski M, Stanimirova I (2010) Recent advances in QSAR studies: methods and applications. In: Puzyn T, Leszczyński J, Cronin MTD (eds) Challenges and advances in computational chemistry and physics, vol 8. Springer, New York, pp 177-205
63. Wang Y, Loo TW, Bartlett MC, Clarke DM (2007) Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 71(3):751-758 (Pubitemid 46294086)
64. Watanabe T, Onuki R, Yamashita S, Taira K, Sugiyama Y (2005) Construction of a functional transporter analysis system using MDR1 knockdown Caco-2 cells. Pharm Res 22(8):1287-1293 (Pubitemid 41176032)
65. Yamashita S, Furubayashi T, Kataoka M, Sakane T, Sezaki H, Tokuda H (2000) Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. Eur J Pharm Sci 10(3):195-204 (Pubitemid 30190095)
66. Zhang L, Zhou W, Li D-H (2006) A descent modified Polak-Ribière- Polyak conjugate gradient method and its global convergence. IMA J Numerl Anal 26(4):629-640 (Pubitemid 44546419)
67. Zhou SF (2008) Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 38(7-8):802-832